Loading...
The 2024 American Society of Clinical Oncology (ASCO) annual meeting, held May 30 to June 3 in Chicago, highlighted important advances in treatment across a broad spectrum of malignancies. Here, NEJM Journal Watch Oncology and Hematology Associate Editor Jyoti D. Patel, MD, FASCO, reviews key trials in lung cancer.
In patients with unresectable EGFR-mutated stage III non–small-cell lung cancer (NSCLC), osimertinib, a third-generation EGFR tyrosine kinase inhibitor, improved progression-free survival (PFS), according to findings from the industry-sponsored, phase 3 LAURA trial published in the New England Journal of Medicine and presented at the ASCO meeting.
Ro…